Literature DB >> 24511016

Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.

Jun Muto1, Yasuhiro Hida, Kichizo Kaga, Kazuto Ohtaka, Shozo Okamoto, Nagara Tamaki, Reiko Nakada-Kubota, Satoshi Hirano, Yoshiro Matsui.   

Abstract

AIM: Surgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography (FDG-PET) is now widely used in clinical diagnosis and staging of various types of cancers, including NSCLC. We investigated whether the maximum standardized uptake value (SUVmax) of primary tumors is useful in predicting the extent of lymph node involvement. PATIENTS AND METHODS: We retrospectively evaluated 354 patients with NSCLC who underwent surgery following FDG-PET and computed tomographic (CT) scans in our hospital. Logistic regression analyses were used to assess associations between categories (age, sex, tumor size, SUVmax, serum Squamous cell carcinoma-related antigen (SCC), cytokeratin 19 fragment (CYFRA), carcinoembryonic antigen (CEA), Brinkman index and histologic type. Differences in SUVmax of primary tumors between positive and negative lymph node involvement were examined by Mann-Whitney U-test.
RESULTS: SUVmax of primary tumors in patients without lymph node involvement was significantly lower than in those with involvement, in both adenocarcinoma and squamous cell carcinomas (median, 2.2 vs. 4.9 in adenocarcinoma and 5.0 vs. 8.1 in squamous cell carcinoma, p<0.001 for both). Among node-positive cases, the lowest primary tumor SUVmax was 1.24 in an adenocarcinoma and 2.05 in a squamous cell carcinoma. However, primary tumor SUVmax and extent of lymph node metastases showed no significant differences between pN1 and pN2, single and multiple lymph node involvement, or single and multiple station involvement.
CONCLUSION: A low primary tumor SUVmax in NSCLC may help identify patients with no lymph node involvement. However, SUVmax does not discriminate between minimal and extended lymph node involvement.

Entities:  

Keywords:  FDG-PET; SUVmax; lymph node involvement; non-small cell lung cancer

Mesh:

Substances:

Year:  2014        PMID: 24511016

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Samuel Hawkins; Olya Stringfield; Matthew B Schabath; Qian Li; Fangyuan Qu; Shichang Liu; Alberto L Garcia; Zhaoxiang Ye; Robert J Gillies
Journal:  Med Phys       Date:  2018-04-29       Impact factor: 4.071

2.  Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.

Authors:  D Marquez-Medina; A Martin-Marco; S Popat
Journal:  Clin Transl Oncol       Date:  2015-07-24       Impact factor: 3.405

3.  FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value.

Authors:  Marina Suárez-Piñera; José Belda-Sanchis; Alvaro Taus; Albert Sánchez-Font; Antoni Mestre-Fusco; Marcel Jiménez; Lara Pijuan
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

4.  Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness.

Authors:  Massimo Moro; Giulia Bertolini; Roberto Caserini; Cristina Borzi; Mattia Boeri; Alessandra Fabbri; Giorgia Leone; Patrizia Gasparini; Carlotta Galeone; Giuseppe Pelosi; Luca Roz; Gabriella Sozzi; Ugo Pastorino
Journal:  Sci Rep       Date:  2017-07-27       Impact factor: 4.379

5.  Evaluation of locoregional invasiveness of small-sized non-small cell lung cancers by enhanced dual-energy computed tomography.

Authors:  Hironori Shimamoto; Shingo Iwano; Hiroyasu Umakoshi; Koji Kawaguchi; Shinji Naganawa
Journal:  Cancer Imaging       Date:  2016-07-26       Impact factor: 3.909

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.